Displaying 49 - 60 of 228
Viral Hepatitis

Gilead: “From Headlines To The Clinic: Expert Approaches To Patient Care in Hepatitis Delta” (Complete Session)

Webcasts
View
General Hepatology

Grifols: "The burden of hepatic encephalopathy and albumin as potential approach" (Complete Session)

Webcasts
View
Viral Hepatitis

GSK: "Looking To The Future Of Hepatitis B: An Expert Review Of Quantitative Hepatitis B Surface Antigen Assessment” (Complete...

Webcasts
View
Metabolism, Alcohol & Toxicity

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Albireo Pharma, an Ipsen Company: “New Horizons in cholestatic liver disease” (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Ipsen: "Scratching beyond the surface in PBC: From current unmet medical needs to future prospects" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Mirum Pharmaceuticals, Inc: "Meet the Experts in Cholestatic Liver Disease" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Discussion and Q&A

Webcasts
View
Metabolism, Alcohol & Toxicity

Introduction

Webcasts
View
Metabolism, Alcohol & Toxicity

NASH: a growing unmet therapeutic need

Webcasts
View
Displaying 49 - 60 of 228